Clinical trial NCT05534347: Angiogenic Biomarkers in Juvenile Idiopathic Arthritis
Official title: Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Juvenile Idiopathic Arthritis (JIA)
Keywords: Juvenile idiopathic arthritis (JIA)
JIA patients in transition towards adult ward
Prognosis of JIA
Severity and structural damage in JIA
Angiogenic and inflammatory biomarkers
Semaphorin (SEMA4A), CCN1
Serum fluid
Synovial fluid
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2022-09-09
Enrollment: 300
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients over (or egal) 16 years old with diagnosis of Juvenile Idiopathic Arthritis starting their follow up in adult rheumatology ward in Cochin hospital

Brief summary: The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.

Detailed description: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. The most common pediatric rheumatologic disease. JIA is the most common pediatric rheumatologic disease. Apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of JIA, especially polyarticular JIA, has been identified. The team has been interested in the prognosis of RA for many years. Thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of RA patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and CCN1 protein. This has been demonstrated in vitro but also in vivo from sera of RA patients. These markers are associated with activity and structural damage in RA.

The project aims to study the interest of these same angiogenic biomarkers in the serum of JIA patients in order to establish whether, as in RA, they are also associated with disease severity.

Eligibility criteria: Inclusion Criteria:

* Greater than or equal to 16 years-old
* Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital
* No-opposition to the research
* Patient with health insurance
* Mastery of the French language

Exclusion Criteria:

* Patient under curatorship or guardianship
* Patient receiving french state medical aid

Primary outcomes:
measure: Dosage of angiogenic markers
timeFrame: 5 years
measure: Dosage of angiogenic markers
timeFrame: 5 years
measure: Dosage of inflammatory markers by ELISA method
timeFrame: 5 years
measure: Dosage of inflammatory markers by ELISA method
timeFrame: 5 years
Secondary outcomes:
measure: Questionnaires
timeFrame: 5 years
measure: Collection of treatments received
timeFrame: 5 years
measure: Structural damage determined by x-rays
timeFrame: 5 years
measure: Angiogenic biomarkers
timeFrame: At inclusion
measure: Inflammatory biomarkers
timeFrame: At inclusion
Other outcomes:
Locations:
city: Paris
country: France
facility: Rheumatology Department, Cochin Hospital
state: IDF
Study officials:
affiliation: Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)
name: Yannick ALLANORE, PD, PhD
role: PRINCIPAL_INVESTIGATOR
References: